NO20022117L - Indazolforbindelser, farmasöytiske preparater, og fremgangsmåte til mediering eller inhibering av celleprofilerasjon - Google Patents

Indazolforbindelser, farmasöytiske preparater, og fremgangsmåte til mediering eller inhibering av celleprofilerasjon

Info

Publication number
NO20022117L
NO20022117L NO20022117A NO20022117A NO20022117L NO 20022117 L NO20022117 L NO 20022117L NO 20022117 A NO20022117 A NO 20022117A NO 20022117 A NO20022117 A NO 20022117A NO 20022117 L NO20022117 L NO 20022117L
Authority
NO
Norway
Prior art keywords
mediating
pharmaceutical preparations
inhibiting cell
indazole compounds
cell profiling
Prior art date
Application number
NO20022117A
Other languages
English (en)
Norwegian (no)
Other versions
NO20022117D0 (no
Inventor
Siegfried Heinz Reich
Ted Michael Bleckman
Susan Elizabeth Kephart
Iii William Henry Romines
Michael Brennan Wallace
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of NO20022117D0 publication Critical patent/NO20022117D0/no
Publication of NO20022117L publication Critical patent/NO20022117L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D41/00—Casting melt-holding vessels, e.g. ladles, tundishes, cups or the like
    • B22D41/50—Pouring-nozzles
    • B22D41/56—Means for supporting, manipulating or changing a pouring-nozzle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20022117A 2000-01-18 2002-05-03 Indazolforbindelser, farmasöytiske preparater, og fremgangsmåte til mediering eller inhibering av celleprofilerasjon NO20022117L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17648400P 2000-01-18 2000-01-18
PCT/US2001/001477 WO2001053268A2 (fr) 2000-01-18 2001-01-18 Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire

Publications (2)

Publication Number Publication Date
NO20022117D0 NO20022117D0 (no) 2002-05-03
NO20022117L true NO20022117L (no) 2002-09-16

Family

ID=22644536

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022117A NO20022117L (no) 2000-01-18 2002-05-03 Indazolforbindelser, farmasöytiske preparater, og fremgangsmåte til mediering eller inhibering av celleprofilerasjon

Country Status (39)

Country Link
US (4) US6555539B2 (fr)
EP (1) EP1250326A2 (fr)
JP (1) JP2003520273A (fr)
KR (1) KR20020073505A (fr)
CN (1) CN1394205A (fr)
AP (1) AP1609A (fr)
AR (1) AR032438A1 (fr)
AU (1) AU785013B2 (fr)
BG (1) BG107011A (fr)
BR (1) BR0107783A (fr)
CA (1) CA2388885A1 (fr)
CO (1) CO5280070A1 (fr)
CR (1) CR6630A (fr)
DO (1) DOP2001000120A (fr)
DZ (1) DZ3301A1 (fr)
EA (1) EA200200768A1 (fr)
EE (1) EE200200398A (fr)
GE (1) GEP20043363B (fr)
GT (1) GT200100009A (fr)
HN (1) HN2001000007A (fr)
HR (1) HRP20020675A2 (fr)
HU (1) HUP0203965A3 (fr)
IL (1) IL150730A0 (fr)
IS (1) IS6474A (fr)
MA (1) MA27589A1 (fr)
MX (1) MXPA02007058A (fr)
MY (1) MY136604A (fr)
NO (1) NO20022117L (fr)
NZ (1) NZ518531A (fr)
OA (1) OA12160A (fr)
PA (1) PA8509901A1 (fr)
PE (1) PE20011334A1 (fr)
PL (1) PL357590A1 (fr)
SK (1) SK10052002A3 (fr)
SV (1) SV2002000293A (fr)
UA (1) UA75880C2 (fr)
WO (1) WO2001053268A2 (fr)
YU (1) YU54202A (fr)
ZA (1) ZA200203040B (fr)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
CZ301750B6 (cs) 1999-12-24 2010-06-09 Aventis Pharma Limited Bicyklický pyrrolový derivát, jeho použití pri výrobe léciva, farmaceutická kompozice tento derivát obsahující a pro použití pri lécení
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
WO2002016348A1 (fr) * 2000-08-09 2002-02-28 Astrazeneca Ab Derives bicycliques antiangiogeniques
ES2302106T3 (es) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
US6982274B2 (en) 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7642278B2 (en) 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
EP1401831A1 (fr) 2001-07-03 2004-03-31 Chiron Corporation Composes d'indazole benzimidazole utilises comme inhibiteurs de tyrosine et de serine/threonine kinase
FR2827861B1 (fr) 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
EP1432416B1 (fr) 2001-09-26 2011-01-19 Pfizer Italia S.r.l. Derives d'aminoindazole agissant comme inhibiteurs de la kinase, procede de production et compositions pharmaceutiques les contenant
JP4637481B2 (ja) 2001-10-19 2011-02-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｃｄｓ１／ｃｈｋ２阻害剤および癌治療における化学療法または放射線療法の補助剤としての２−フェニルベンズイミダゾールおよびイミダゾ−［４，５］−ピリジン
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
FR2831537B1 (fr) * 2001-10-26 2008-02-29 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
IL161576A0 (en) * 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US6867320B2 (en) * 2002-02-21 2005-03-15 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivatives and use thereof
NZ535349A (en) * 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
MXPA04011851A (es) * 2002-05-30 2005-03-31 Celgene Corp Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos.
IL164209A0 (en) * 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
JP2004075673A (ja) * 2002-06-19 2004-03-11 Mitsubishi Chemicals Corp 化合物およびこれを用いた有機電界発光素子
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
EP1545515A1 (fr) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
EP1582211A1 (fr) * 2002-12-03 2005-10-05 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de jnk
EA008501B1 (ru) 2002-12-19 2007-06-29 Пфайзер Инк. 2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
BRPI0407618A (pt) * 2003-02-21 2006-02-21 Pfizer derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
DE602004029145D1 (de) 2003-02-27 2010-10-28 Palau Pharma Sa Pyrazolopyridin-derivate
ES2214150B1 (es) * 2003-02-27 2005-12-01 J. URIACH & CIA S.A. "nuevos derivados de pirazolopiridinas".
DE602004006852D1 (de) 2003-04-17 2007-07-19 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5ü-pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
ITRM20030355A1 (it) * 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
KR101204247B1 (ko) 2003-07-22 2012-11-22 아스텍스 테라퓨틱스 리미티드 3,4-이치환된 1ｈ-피라졸 화합물 및 그의 시클린 의존성키나제 (ｃｄｋ) 및 글리코겐 합성효소 키나제-3(ｇｓｋ-3) 조정제로서 용도
CA2518951A1 (fr) * 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de la proteine kinase
EP1652842B1 (fr) * 2003-07-30 2012-04-11 Kyowa Hakko Kirin Co., Ltd. Derivés d'Indazole
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7511145B2 (en) * 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
US20050113576A1 (en) * 2003-08-05 2005-05-26 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2005014554A1 (fr) * 2003-08-08 2005-02-17 Astex Therapeutics Limited Composes 1h-indazole-3-carboxamide utilises comme modulateurs de la mapkap kinase
EP1660427A4 (fr) 2003-08-14 2006-12-20 Asahi Kasei Pharma Corp Derive d'acide arylalcanoique substitue et son utilisation
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
MY144339A (en) * 2003-09-08 2011-08-29 Aventis Pharma Inc Thienopyrazoles
TWI344961B (en) * 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
BRPI0416266A (pt) * 2003-11-06 2007-01-09 Celgene Corp método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente
EP2762475A1 (fr) 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Sels pharmaceutiquement acceptables de composés de quinoline et leur utilisation médicale
US20060179711A1 (en) * 2003-11-17 2006-08-17 Aerogrow International, Inc. Devices and methods for growing plants
EP2065383A1 (fr) 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Composés d'indazoles et procédés d'utilisation associés en tant qu'inhibiteurs de kinase de protéine
US7488817B2 (en) * 2004-02-02 2009-02-10 The Trustees Of The University Of Pennsylvania Metal complex protein kinase inhibitors
WO2005094823A1 (fr) * 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. INHIBITEUR DE Flt-3
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
GB0409080D0 (en) * 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
AU2005266494B2 (en) * 2004-07-27 2009-09-10 Novartis Ag Inhibitors of Hsp90
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
FR2876584B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20060116519A1 (en) * 2004-11-17 2006-06-01 Agouron Pharmaceuticals, Inc. Synthesis of 5-bromo-4-methyl-pyridin-3-ylmethyl)-ethyl-carbamic acid tert-butyl ester
WO2006054143A1 (fr) * 2004-11-17 2006-05-26 Pfizer Inc. Formes polymorphes de {5-[3-(4,6-difluoro-1h-benzimidazol-2-yl)-1h-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
CA2588558A1 (fr) * 2004-11-23 2006-06-01 Celgene Corporation Procedes et compositions permettant d'utiliser des inhibiteurs jnk pour traiter et gerer une blessure du systeme nerveux central
AU2005321091B2 (en) 2004-12-30 2012-04-12 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases
US20080161251A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
JP5475235B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
CA2596527C (fr) 2005-01-27 2013-02-12 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur d'igf-1r
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
PT1869020E (pt) 2005-03-29 2010-12-23 Icos Corp Derivados de heteroaril-ureia úteis para a inibição de chk1
JP2008540345A (ja) * 2005-04-29 2008-11-20 セルジーン・コーポレーション １−（５−（１ｈ−１，２，４−トリアゾール−５−イル）（１ｈ−インダゾール−３−イル））−３−（２−ピペリジルエトキシ）ベンゼンの固体形態
ATE530533T1 (de) 2005-05-17 2011-11-15 Novartis Ag Verfahren zur synthese heterocyclischer verbindungen
WO2006130673A1 (fr) 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines utilisees pour traiter des troubles dont la mediation est assuree par des kinases
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
WO2007058626A1 (fr) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Composes d'indazole
PT1957074E (pt) 2005-11-29 2014-06-25 Novartis Ag Formulações de quinolinonas
KR20070077468A (ko) * 2006-01-23 2007-07-26 크리스탈지노믹스(주) 단백질 키나아제 활성을 저해하는 이미다조피리딘 유도체,이의 제조방법 및 이를 함유하는 약학 조성물
AU2007213452A1 (en) * 2006-02-10 2007-08-16 Biomarin Iga Limited Treatment of Duchenne muscular dystrophy
JP2009530337A (ja) * 2006-03-23 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー 置換インダゾール誘導体、その製造方法、及びその薬剤としての利用法
CN101484427A (zh) 2006-06-30 2009-07-15 协和发酵麒麟株式会社 Abl激酶抑制剂
US20090209537A1 (en) * 2006-06-30 2009-08-20 Kyowa Hakko Kirin Co., Ltd. Aurora inhibitors
JPWO2008020606A1 (ja) * 2006-08-16 2010-01-07 協和発酵キリン株式会社 血管新生阻害剤
CA2661898A1 (fr) * 2006-08-25 2008-02-28 Abbott Laboratories Derives d'indazole inhibant trpv1, et leur utilisation
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
CA2664335C (fr) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Inhibiteurs de la rho-kinase
EP2073803B1 (fr) 2006-10-12 2018-09-19 Astex Therapeutics Limited Combinaisons pharmaceutiques
WO2008044045A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
JP2010513557A (ja) * 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
WO2008106594A2 (fr) * 2007-02-28 2008-09-04 The Arizona Board Of Regents, On Behalf Of The University Of Arizona Inhibiteurs de la nucléophosmine (npm) et procédés d'induction de l'apoptose
CN101622015A (zh) 2007-03-05 2010-01-06 协和发酵麒麟株式会社 药物组合物
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
EP2214675B1 (fr) 2007-10-25 2013-11-20 Genentech, Inc. Procédé de préparation de composés de thiénopyrimidine
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
EP2323989A4 (fr) * 2008-03-20 2011-06-22 Abbott Lab Procédés de préparation d'agents destinés au système nerveux central qui sont des antagonistes des trpv1
KR101269393B1 (ko) 2008-04-28 2013-05-29 아사히 가세이 파마 가부시키가이샤 페닐프로피온산 유도체 및 이의 용도
US8106039B2 (en) * 2008-04-30 2012-01-31 The Trustees Of The University Of Pennsylvania Metal complex phosphatidyl-inositol-3-kinase inhibitors
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
ES2553827T3 (es) 2009-05-01 2015-12-14 Aerie Pharmaceuticals, Inc. Inhibidores de mecanismo doble para el tratamiento de enfermedad
JP2013501792A (ja) * 2009-08-10 2013-01-17 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用
DK2987487T3 (da) * 2009-08-10 2020-12-07 Samumed Llc Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf
UY33001A (es) 2009-11-06 2011-05-31 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
CA2986631C (fr) 2009-12-21 2020-06-02 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines et leurs utilisations therapeutiques
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
WO2012020725A1 (fr) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Dérivé hétérocyclique présentant un antagonisme pour le récepteur npy y5
ES2879314T3 (es) 2010-08-18 2021-11-22 Biosplice Therapeutics Inc Dicetonas e hidroxicetonas como activadores de la vía de señalización de catenina
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
CA2819373A1 (fr) 2010-12-09 2012-06-14 Amgen Inc. Composes bicycliques en tant qu'inhibiteurs de pim
WO2012129338A1 (fr) 2011-03-22 2012-09-27 Amgen Inc. Composés d'azole utilisés en tant qu'inhibiteurs des pim
JP2014509660A (ja) * 2011-04-01 2014-04-21 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション ＰＤＫ１キナーゼの阻害剤としての置換３−（１Ｈ−ベンゾ｛ｄ｝イミダゾール−２−イル）−１Ｈ−インダゾール類似体
BR112014006127A2 (pt) 2011-09-14 2017-04-04 Samumed Llc indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização wnt/b-catenina
WO2013063321A1 (fr) 2011-10-25 2013-05-02 The General Hospital Corporation Inhibiteurs de la voie wnt/b-caténine et leurs procédés d'utilisation
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
CN104271133B (zh) 2012-05-04 2017-10-13 萨穆梅德有限公司 1H‑吡唑并[3,4‑b]吡啶及其治疗应用
WO2014041518A1 (fr) * 2012-09-14 2014-03-20 Glenmark Pharmaceuticals S.A. Composés thiénopyrrole comme inhibiteurs de l'itk
EP2943198B1 (fr) 2013-01-08 2019-07-17 Samumed, LLC Inhibiteurs de 3-(benzoimidazol-2-yl)-indazole de la voie de signalisation par wnt et leurs utilisations thérapeutiques
CN104370889A (zh) * 2013-01-24 2015-02-25 韩冰 一类降低眼压的化合物及其制备方法和用途
JP6401189B2 (ja) 2013-02-22 2018-10-03 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔ／β−カテニンシグナル伝達経路活性化剤としてのγ−ジケトン
WO2014134774A1 (fr) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
WO2014134776A1 (fr) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
US9440952B2 (en) 2013-03-04 2016-09-13 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014134772A1 (fr) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
CN109528721B (zh) 2013-03-15 2021-10-01 爱瑞制药公司 联合治疗
EP3027605B1 (fr) 2013-07-31 2017-11-08 Council of Scientific & Industrial Research Nouveaux composés d'indazole et leur procede de preparation
KR102195494B1 (ko) 2013-10-18 2020-12-28 유니버시티 헬스 네트워크 췌장암 치료
CN106687454B8 (zh) 2014-07-24 2019-08-30 贝达医药公司 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途
EP3206686B1 (fr) 2014-08-20 2019-10-09 Samumed, LLC Gamma-dicétones pour le traitement et la prévention des rides et du vieillissement de la peau
WO2016040180A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040182A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques
WO2016040188A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040181A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040184A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine et ses utilisations thérapeutiques
WO2016040193A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
WO2016040185A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 2-1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine et ses utilisations thérapeutiques
WO2016040190A1 (fr) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine et ses utilisations thérapeutiques
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017024004A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
WO2017024015A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023993A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023986A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles et leurs utilisations thérapeutiques
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023989A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023988A1 (fr) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
CN107922349B (zh) * 2015-08-07 2021-05-07 哈尔滨珍宝制药有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
WO2017079759A1 (fr) 2015-11-06 2017-05-11 Samumed, Llc 2-(3h-indazol-3-yl)-1h-imidazo[4,5-c]pyridines et leurs utilisations anti-inflammatoires
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
JP6832946B2 (ja) 2015-11-17 2021-02-24 アエリエ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤およびその中間体の調製方法
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
CN109476660B (zh) 2016-06-01 2023-04-04 拜斯丽治疗有限公司 N-(5-(3-(7-(3-氟苯基)-3h-咪唑并[4,5-c]吡啶-2-基)-1h-吲唑-5-基)吡啶-3-基)-3-甲基丁酰胺的制备方法
US11078192B2 (en) 2016-07-05 2021-08-03 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
WO2018013430A2 (fr) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Composés hétérocycliques pour le traitement d'une infection à arenavirus
EP3506890A1 (fr) 2016-08-31 2019-07-10 Aerie Pharmaceuticals, Inc. Compositions ophtalmiques
CA3041291A1 (fr) * 2016-10-21 2018-04-26 Samumed, Llc Procedes d'utilisation d'indazole-3-carboxamides et leur utilisation en tant qu'inhibiteurs de la voie de signalisation wnt/s-catenine
US10758523B2 (en) 2016-11-07 2020-09-01 Samumed, Llc Single-dose, ready-to-use injectable formulations
SG11201908179UA (en) 2017-03-31 2019-10-30 Aerie Pharmaceuticals Inc Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
WO2019084497A1 (fr) 2017-10-27 2019-05-02 Samumed, Llc 6-(hétéroaryle et aryle à 6 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
JP7293560B2 (ja) 2017-12-29 2023-06-20 グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド 芳香族ビニルまたは芳香族エチル系誘導体、その製造方法、中間体、薬物組成物および使用
BR112020017087A2 (pt) 2018-02-23 2020-12-22 Samumed, Llc Indazol-3-carboxamidas substituídas 5-heteroarila e preparação e uso das mesmas
US10759799B2 (en) 2018-06-15 2020-09-01 Samumed, Llc Indazole containing macrocycles and therapeutic uses thereof
WO2020056345A1 (fr) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
WO2020150545A1 (fr) 2019-01-17 2020-07-23 Samumed, Llc DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
WO2021088859A1 (fr) * 2019-11-06 2021-05-14 暨南大学 Composé d'indazole, composition pharmaceutique de celui-ci et ses applications
WO2021125229A1 (fr) * 2019-12-17 2021-06-24 富士フイルム株式会社 Composé d'indazole ou sel de celui-ci, et composition pharmaceutique
WO2021121420A1 (fr) * 2019-12-20 2021-06-24 江苏凯迪恩医药科技有限公司 Composé benzopyrazole et intermédiaire, procédé de préparation correspondant et utilisation associée
WO2021168341A1 (fr) 2020-02-21 2021-08-26 Samumed, Llc Formes solides de 1-(5-(3-(7-(3-fluorophényl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-n,n-diméthylméthanamine
CN112724134B (zh) * 2021-01-14 2022-04-01 复旦大学 氮杂吲唑联吡啶衍生物髓细胞增殖抑制剂及其制备方法与在制药中的应用
WO2023240138A1 (fr) * 2022-06-08 2023-12-14 Blossomhill Therapeutics, Inc. Macrocycles contenant de l'indazole et leur utilisation

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1376600A (en) 1971-02-15 1974-12-04 Agfa Gevaert Photographic developer compositions
CH575397A5 (fr) 1971-11-09 1976-05-14 Basf Ag
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
FR2265739B1 (fr) 1974-03-29 1976-12-17 Ugine Kuhlmann
JPS5615287A (en) 1979-07-16 1981-02-14 Chugai Pharmaceut Co Ltd Pyrazoloindazole derivative and its preparation
EP0104029B1 (fr) 1982-09-17 1988-08-24 Kudelski S.A. Dispositif de commande pour un moteur électrique
JPS59228248A (ja) 1983-06-08 1984-12-21 Konishiroku Photo Ind Co Ltd 直接ポジ用ハロゲン化銀写真感光材料
JPS604184A (ja) * 1983-06-23 1985-01-10 Chugai Pharmaceut Co Ltd ピラゾロインダゾ−ル誘導体
JPH083564B2 (ja) 1986-07-25 1996-01-17 三菱化学株式会社 偏光フィルム
DE3842091A1 (de) * 1987-12-14 1989-07-13 Fuji Photo Film Co Ltd Bilderzeugungsverfahren
EP0477436B1 (fr) 1990-09-24 1995-12-13 Agfa-Gevaert N.V. Matériau photographique à l'halogénure d'argent autopositif, sensible aux ultraviolets et pouvant être manipulé à la lumière de chambre
US5208248A (en) * 1991-01-11 1993-05-04 Merck Sharpe & Dohme, Ltd. Indazole-substituted five-membered heteroaromatic compounds
EP0494774A1 (fr) 1991-01-11 1992-07-15 MERCK SHARP & DOHME LTD. Composés hétéroaromatiques à 5 chaînons substitués par l'indazole
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
AU5704594A (en) 1992-12-18 1994-07-19 Wellcome Foundation Limited, The Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
DE69532817T2 (de) 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
ZA951822B (en) * 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
KR19980701879A (ko) 1995-02-02 1998-06-25 피터 기딩스 5-히드록시트립타민 수용체 길항제로서의 인돌 유도체
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6495526B2 (en) 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
WO1997034876A1 (fr) 1996-03-15 1997-09-25 Zeneca Limited Derives de cinnoline et leur emploi comme medicaments
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
WO1998033798A2 (fr) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3d]pyrimidines et 4-aminopyrimidines en tant qu'inhibiteurs de la proliferation cellulaire
AU6230098A (en) 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
JP2001518094A (ja) 1997-03-31 2001-10-09 デュポン ファーマシューティカルズ カンパニー Ｈｉｖプロテアーゼ阻害剤として有用なインダゾール−環式尿素
CA2294244A1 (fr) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Derives de purine inhibant la kinase dependant de la cycline
GB9716324D0 (en) 1997-08-01 1997-10-08 Mead Corp Packaging machine and method of carton set up
FR2767475A1 (fr) 1997-08-25 1999-02-26 Oreal Compositions de teinture des fibres keratiniques contenant des derives d'indazoles et procede
FR2767827A1 (fr) 1997-09-03 1999-02-26 Adir Nouveaux derives de l'indole et de l'indazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU9691198A (en) * 1997-10-06 1999-04-27 Basf Aktiengesellschaft Indeno{1,2-c}-, naphtho{1,2-c}- and benzo{6,7}cyclohepta{1,2-c}pyrazole derivatives
BR9815200A (pt) 1997-10-27 2001-10-16 Agouron Pharma Composto, composição farmacêutica e método de tratamento de uma doença ou distúrbio mediado pela inibição de cdk4 ou um complexo de cdk4/ciclina
IL135900A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
NZ503995A (en) 1997-11-04 2003-02-28 Pfizer Prod Inc Indazole compounds, and pharmaceutical compositions and uses thereof, based on indazole bioisostere replacement of catechol in PDE4 inhibitors
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
HUP0100931A3 (en) 1998-02-26 2002-08-28 Aventis Pharma Inc 6,9-disubstituted 2-[trans-(-aminocyclohexyl)amino]purines and pharmaceutical compositions containing them
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
EA003603B1 (ru) 1998-02-27 2003-06-26 Пфайзер Продактс Инк. N-[(замещенное пятичленное ди- или триазадиненасыщенное кольцо) карбонил] гуанидиновые производные для лечения ишемии
JP4665239B2 (ja) 1998-04-21 2011-04-06 アゲンニクス アーゲー 抗癌剤および抗増殖性薬剤としての５−アミノインデノ［１，２−ｃ］ピラゾール−４−オン
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
EP1545515A1 (fr) * 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles et 3-pyrrolyl-indazoles utilises en tant que nouveaux inhibiteurs de la proteine kinase

Also Published As

Publication number Publication date
WO2001053268B1 (fr) 2002-01-24
BG107011A (bg) 2003-04-30
YU54202A (sh) 2006-01-16
NZ518531A (en) 2004-09-24
DZ3301A1 (fr) 2001-07-26
EE200200398A (et) 2003-10-15
CA2388885A1 (fr) 2001-07-26
CN1394205A (zh) 2003-01-29
MXPA02007058A (es) 2003-01-28
US6919461B2 (en) 2005-07-19
ZA200203040B (en) 2003-08-11
HUP0203965A2 (en) 2003-05-28
NO20022117D0 (no) 2002-05-03
CO5280070A1 (es) 2003-05-30
KR20020073505A (ko) 2002-09-26
PL357590A1 (en) 2004-07-26
AP2002002564A0 (en) 2002-06-30
PA8509901A1 (es) 2002-08-26
CR6630A (es) 2004-01-29
SV2002000293A (es) 2002-12-02
EA200200768A1 (ru) 2003-02-27
DOP2001000120A (es) 2002-04-15
UA75880C2 (en) 2006-06-15
MY136604A (en) 2008-10-31
JP2003520273A (ja) 2003-07-02
PE20011334A1 (es) 2002-01-14
AR032438A1 (es) 2003-11-12
US7232912B2 (en) 2007-06-19
HUP0203965A3 (en) 2003-07-28
US20060111322A1 (en) 2006-05-25
US20030139463A1 (en) 2003-07-24
AU785013B2 (en) 2006-08-24
WO2001053268A3 (fr) 2001-12-27
US6555539B2 (en) 2003-04-29
GT200100009A (es) 2002-03-14
OA12160A (en) 2006-05-08
GEP20043363B (en) 2004-05-10
US20020161022A1 (en) 2002-10-31
HN2001000007A (es) 2001-06-13
AP1609A (en) 2006-05-08
SK10052002A3 (sk) 2003-03-04
WO2001053268A2 (fr) 2001-07-26
AU2953901A (en) 2001-07-31
MA27589A1 (fr) 2005-11-01
IS6474A (is) 2002-07-16
EP1250326A2 (fr) 2002-10-23
BR0107783A (pt) 2002-11-19
US20050239855A1 (en) 2005-10-27
HRP20020675A2 (en) 2004-12-31
IL150730A0 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
NO20022117L (no) Indazolforbindelser, farmasöytiske preparater, og fremgangsmåte til mediering eller inhibering av celleprofilerasjon
NO20015797L (no) Indazolforbindelser og farmasöytiske forbindelser for inhibering av proteinkinaser, og fremgangsmåter til anvendelsederav
IS8214A (is) 3,5 tvísetin indasól enfasambönd, lyfjasamsetningar, og aðferðir til að miðla eða hindra frumufjölgun
NO20030381D0 (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
DK1345910T3 (da) Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
NO20005430D0 (no) 1-[(1-substituerte-4-piperidinyl)metyl]-4-piperidinderivater, fremgangsmÕter for fremstilling av disse, medisinske preparater inneholdende dem, og mellomprodukter
NO20016277L (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
NO996250D0 (no) Nye hydrazidforbindelser, fremgangsmåte ved deres fremstilling og farmasoeytiske sammensetninger inneholdende dem
DK1337529T3 (da) Heterocyclylalkylpiperidinderivater, deres fremstilling og præparater indeholdende dem
NO20031152D0 (no) Befruktningshindrende fremgangsmåte og administrasjonsform for det samme
NO20024176L (no) Farmasöytiske preparater inneholder derivater av 3-amino- azetidin, de nye derivater og deres fremstilling
DK1112251T3 (da) Azetidinderivater, deres fremstilling og medikamenter indeholdende disse derivater
DK1268431T3 (da) 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer
NO20011950L (no) Farmasöytiske blandinger som inneholder poly(ADP-ribose) glukohydrolaseinhibitorer og fremgangsmåter for anvendelse avsamme
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
IS6531A (is) Aðferðir til að búa til klaríþrómýsín og klaríþrómýsínmilliefni, í megindráttum oxímlaust klaríþrómýsín og lyfjablanda sem inniheldur það
NO20041058L (no) Preparater og fremgangsmater relatert til nye benzodiazepinforbindelser og mal derav
DK1246807T3 (da) Hydantoin-, thiohydantoin-, purimidindion- og thioxopyrimidinonderivater, fremgangsmåder til deres fremstilling og deres anvendelse som lægemidler
DK1311731T3 (da) Fremgangsmåde og arrangement til stolpesystem
IS7266A (is) Lyfjaform sem innihalda sýru-óþolin virk efni og aðferðir til tilreiðslu þeirra
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer